Amide Technologies is a technology company.
Amide Technologies has raised $8.0M across 1 funding round.
Amide Technologies has raised $8.0M in total across 1 funding round.
Amide Technologies has raised $8.0M in total across 1 funding round.
Amide Technologies's investors include Sierra Point Ventures, The Engine.
Amide Technologies is a biotechnology company specializing in on-demand manufacturing of complex peptides that are difficult or impossible to produce via traditional methods.[1][2][4] It serves pharmaceutical and biotech researchers by enabling rapid synthesis of peptides up to 120+ amino acids, including hydrophobic, cyclic, branched, and mirror-image structures, with delivery in as little as four days and a >99% on-time rate, accelerating drug discovery cycles.[1][4][5] Developed at MIT, the company has raised $16.5 million in funding, including a $7.5 million Series A extension in July 2023 led by Engine Ventures, demonstrating strong growth momentum in peptide therapeutics.[1][3]
Amide Technologies originated from MIT labs in 2016, founded by chemistry professor Brad Pentelute and his graduate student Mark Simon, who developed breakthroughs in automated fast-flow peptide synthesis (AFPS) to match ribosomal efficiency.[1][2][5] Their work addressed limitations in solid-phase peptide synthesis (SPPS), enabling rapid production of challenging peptides; early traction came from proving synthesis of complex structures unattainable by cells or standard methods.[2][5] Investor Jeremy Wertheimer, former ITA Software founder and Google VP of Engineering, joined to commercialize the tech, with Mark Simon now CEO and Pentelute leading growth.[1][2]
Amide stands out through its fusion of robotics, AI, and chemistry in AFPS, outperforming traditional SPPS:
Amide rides the peptide therapeutics boom, where peptides offer precise targeting for diseases like cancer and metabolic disorders, fueled by demand for novel modalities beyond antibodies or small molecules.[1][2] Timing aligns with AI-driven drug design and automation in biotech, as flow chemistry scales manufacturing amid biopharma's push for faster iteration—peptides now represent a growing $50B+ market.[1][5] Market forces like supply chain bottlenecks for custom peptides favor Amide, influencing the ecosystem by unlocking "frontier" structures that speed clinical programs and expand therapeutic possibilities.[2][4]
Amide is poised to dominate complex peptide supply as biopharma scales AI-optimized drug discovery, with GMP manufacturing in planning to enter clinical production.[5] Trends like mirror-image proteins for stable therapeutics and robotic synthesis will propel growth, potentially capturing share from legacy vendors. Its influence may evolve from R&D enabler to full-scale CDMO, tying back to its MIT roots in revolutionizing synthesis speed for global drug innovation.[1][5]
Amide Technologies has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Series A in July 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2023 | $8.0M Series A | Sierra Point Ventures, The Engine |